Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...
Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment Biktarvy and its new long-acting pre-exposure prophylaxis (PrEP) medicine ...
Here are four things to know. 1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections. 2. The drug’s wholesale price will be about $36,000 per year, which falls in line ...
Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' (GILD.O), opens new tab top-selling drug Biktarvy ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or substance use disorders. Medicare claims data analysis indicates B/F/TAF has ...
On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback